Free tool
FAERS Monitor: Cyramza
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125477 or its brand name (Cyramza, Ramucirumab). Reports on generic versions are filed under their own applications.
Reports
6,320
Serious
5,943
94% of reports
Hospitalization
2,396
Death reported
1,693
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- malignant neoplasm progression817
- death614
- interstitial lung disease301
- neutropenia268
- febrile neutropenia265
- decreased appetite234
- diarrhoea229
- off label use218
- nausea209
- disease progression204
- fatigue203
- hypertension194
- pyrexia191
- ascites181
- neutrophil count decreased179
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 5 |
| 2012 | 17 |
| 2013 | 13 |
| 2014 | 131 |
| 2015 | 405 |
| 2016 | 471 |
| 2017 | 621 |
| 2018 | 687 |
| 2019 | 630 |
| 2020 | 519 |
| 2021 | 628 |
| 2022 | 533 |
| 2023 | 502 |
| 2024 | 474 |
| 2025 | 386 |
| 2026 | 298 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,839 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| malignant neoplasm progressionSignal | 817 | 26.8 | 25.1 | 20,167 |
| interstitial lung diseaseSignal | 301 | 20.8 | 18.6 | 5,635 |
| ascitesSignal | 181 | 20.6 | 17.8 | 3,342 |
| neutrophil count decreasedSignal | 179 | 14.7 | 12.7 | 2,262 |
| febrile neutropeniaSignal | 265 | 13.3 | 11.9 | 3,011 |
| neutropeniaSignal | 268 | 6.6 | 5.8 | 1,266 |
| disease progressionSignal | 204 | 5.7 | 5.0 | 798 |
| decreased appetiteSignal | 234 | 3.4 | 3.0 | 388 |
| hypertensionSignal | 194 | 3.1 | 2.7 | 268 |
| deathSignal | 614 | 2.4 | 2.2 | 507 |
| pyrexia | 191 | 1.8 | 1.6 | 73 |
| diarrhoea | 229 | 1.2 | 1.0 | 6 |
| nausea | 209 | 0.9 | 0.8 | 4 |
| fatigue | 203 | 0.9 | 0.8 | 4 |
| off label use | 218 | 0.8 | 0.7 | 8 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.